Topic Listing for Neurobiological Technologies

Abbott Laboratories Viprinex Absence Appraisal Rights
Absence Appraisal Rights See Page Abstentions Broker Non-votes
Acceptance Acceptance Drug Product
Acceptance Employment Offer Acceptance Work Product
Accounting Treatment Acquired In-process Research Development
Acquired In-process Research Development Expense Acquisition Empire Pharmaceuticals Inc
Acquisition Empire Pharmaceuticals Inc Restated See Acquisitions New Product Candidates Result Operating Difficulties Harm
Adjournment Special Meeting Necessary Solicit Additional Proxies Not Adjustments Changes Capitalization Merger Change Control
Adoption Stockholder Rights Plan Adopts Stockholder Rights Plan
Aggregated Option Exercises 2005 Year-end Values Aggregated Option Exercises 2006 Year-end Values
Agreement Agreement Buck Institute
Agreement Commercial Manufacture Supply Medicinal Product Agreement Effective 1st 2005 Date Between
Air Allocation Compensation
Alternative Dispute Resolution Injunction Amend Restate 2003 Equity Incentive Plan
Amendment Amendment Charter Not Approved Liquidating Distributions Delayed
Amendment Commercial Lease Amendment Loan Security Agreement
Amendment Modification Abandonment Plan Dissolution Amendment Modification Abandonment Plan Dissolution See Page
Amendment Not Approved See Page Amendment Restatement Bylaws
Amendment Rights Agreement Amendment Termination Plan
Amendments Amount Distribute Stockholders Pursuant Plan Dissolution Substantially Less
Annual Report Appendices
Appendix Applicable Law Place Arbitration
Approval Dissolution Pursuant Plan Approval Plan Complete Liquidation Dissolution
Approval Required Approval Viprinex Future Product Candidate Fda Other Regulatory
Approval Xerecept Only Investigational Drug Retain Interest Fda Asp Phase Clinical Trials
Assignment Form Attention Thomas Heagney
Attrition Cancellation Fees Auction Rate Securities Hold Portfolio Currently Not Actively
Audit Committee Audit Fees
Authority Authority Directors
Authority Directors See Page Available Information Website Address
Back-up Withholding Background
Background Proposed Dissolution Liquidation Bank National Association Trustee
Basic Diluted Net Income Loss Per Share Basic Diluted Net Loss Per Share
Basic Principles Basis Presentation
Baxter Pharmaceutical Solutions Llc Because Not Own Manufacturing Facilities Face Risks Outsourcing
Beneficial Ownership Reporting Compliance Between Neurobiological Technologies Inc Paul Freiman
Biostatistics Costs Biostatistics Sas Programming Assumptions
Board Abandon Implementation Plan Dissolution Even Pursuant Approved Board Committees
Board Directors Committees Board Directors Recommends Vote Nominees Listed Below
Board Meetings Committees Board Members Potential Conflict Interest Recommending Approval Amendment
Board Members Potential Conflict Interest Recommending Approval Dissolution Bonus Payments
Bonus Plan Bridge Financing
Buck Institute Neurobiological Technologies Inc Partner Develop Treatment Building Rules Regulations
Business Description Basis Presentation Business Strategy
Cancellation Capital Stock Cancellation Capital Stock See Page
Capital Stock Captions
Cash Compensation Elements Cash Equivalents Investments
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Ceilings
Celtic Pharma Completes Acquisition Exclusive Worldwide Rights Xerecept Celtic Pharma Holdings
Celtic Pharma Holdings Xerecept Celtic Pharma Not Successful Selling Rights Xerecept
Centre National Recherche Scientifique Certain Considerations
Certain Considerations Holders Common Stock Certain Considerations Holders Preferred Stock
Certain Federal Income Tax Consequences Reverse Split Certain Material Federal Income Tax Considerations
Certain Material Federal Income Tax Considerations See Page Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Transactions
Certificate Amendment Amended Restated Incorporation Neurobiological Technologies Inc Certificate Incorporation Bylaws Delaware Law Stockholder Rights Plan
Certificates Analysis Manufacturing Compliance Certification
Cessation Trading Common Stock Cessation Trading Common Stock See Page
Change Orders Change Results Reported Earnings
Change-in-control Arrangements Changes Base Salary
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Changes Production Choice Law Dispute Resolution
Class Directors Continuing Office Until 2007 Annual Meeting Class Directors Continuing Office Until 2008 Annual Meeting
Class Directors Continuing Office Until 2009 Annual Meeting Class Directors Continuing Office Until 2010 Annual Meeting
Class Nominees Election Three-year Term Expiring 2009 Annual Class Nominees Election Three-year Term Expiring 2010 Annual
Class Nominees Election Three-year Term Expiring 2011 Annual Classification Board Directors
Classification Directors Clinical Supplies
Clinical Trials Marketing Potential Products Expose Liability Claims Clinical Trials Viprinex Delayed Because Patient Enrollment Other
Close Sale Rights Assets Related Xerecept Pursuant Agreement Closing Transfer Books
Closing Transfer Books See Page Cmccs Responsibilities Obligations
Code Business Conduct Ethics Code Conduct
Collaboration Agreement Collaboration Agreements
Commencement Letter Commitments Contingencies
Common Stock Common Stock Delisted Nasdaq Capital Market Negatively Impact
Common Stock Reserved Future Issuance Common Stock Transactions
Compensation Compensation Chief Executive Officer
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Compensation Named Executive Officers Compensation Payments Schedule
Compensation Philosophy Objectives Competition
Competitive Market Benchmarking Complete Sale Rights Assets Related Xerecept Expected Dependent
Compliance Nasdaq Listing Standards Composition
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Other Risks Uncertainties Conclusion
Condensed Consolidated Statement Operations Condensed Consolidated Statements Operations
Condensed Statements Operations Conditions
Conduct Following Dissolution Conduct Following Dissolution See Page
Conference Call 1030 Conference Call Information
Conference Call Scheduled 1030 730 Conference Call Scheduled 1100 800
Confidential Confidential Information
Confidentiality Conflicts Debarment Financial Disclosures
Consent Consent Agreement Cnrs
Consent Independent Registered Public Accounting Firm Contact Persons
Content Contents
Contingencies Contingency Reserve
Contingency Reserve See Page Continue Incur Expenses Complying Public Reporting Requirements Economically
Contract Contractual Commitments
Contractual Obligations Controls Procedures
Convertible Preferred Stock Coordination Further Action Parties
Copies Existing Permits Corporate Governance Guidelines
Corporation Cost Estimates
Cost Payment Schedule Covenants
Criteria Used Decision Apply Reverse Stock Split Critical Accounting Policies
Cumulative Total Return Data Management Datafax Costs
Data Management Fax Biostatistics Payment Schedule Debt Equity Financing
Decide Liquidating Trust Interests Stockholders Such Not Transferable Definitions
Delaware Limited Partnership Departure Directors Principal Officers Election Appointment
Departure Directors Principal Officers Election Appointment Certain Dependent Celtic Entities Development Commercialization Xerecept
Dependent Merz Marketing Partners Forest Lundbeck Successful Commercialization Derivative Financial Instruments
Description Business Difficult Integrate Acquired Companies Products Technologies Personnel Operations
Director Compensation Director Independence
Directors Directors Officers
Dissenters Rights Dissolution Delaware Law
Dissolution Liquidation Dissolution Liquidation See Page
Documentation Documentation Defective Products
Documents Incorporated Reference Doors Frames Hardware Windows
Dosing Drug Product Recalls
Duration Termination Each Stockholder Consult His Her Own Tax Advisers
Early Termination Election Class Directors
Election Directors Election Officer
Elective Dissolution Process Employee Stock Purchase Plan
Employees Employment Agreement
Employment Contracts Change-in-control Arrangements End Page
Entirety Entry Material Definitive Agreement
Equity Awards Equity Compensation
Equity Compensation Plan Information Equity Financing Warrants
Equity Transactions Escrow Terms
Estimated Expenses Snake Farm Estimated Liquidating Distributions
Estimated Liquidating Distributions See Page Estimates
Estimates Involved Determining Fair Value Investments Eurobiological Echnologies
Evaluation Disclosure Controls Procedures Even Granted Fda Approval Product Candidates Not Able
Even Other Product Candidates Approved Commercialization Not Successfully Even Viprinex Approved Commercialization Not Successfully Commercialized
Even Viprinex Approved Commercialization Not Successfully Commercialized Generate Even Xerecept Approved Commercialization Not Successfully Commercialized Generate
Exact Name Registrant Specified Charter Executive Compensation
Executive Officers Exhibits
Existing Agreements Expect Need Raise Additional Capital Fund Ongoing Operations
Expect Terminate Registration Common Stock Exchange Act Substantially Expenses Taxes
Explanatory Face Intense Competition Other Companies
Face Security Fair Value Financial Instruments
Federal Income Tax Consequences Options Stock Awards Plan Fees Payments
Filed Copy Certificate Been Forwarded New Castle County Filing Tax Returns Forms Other Reports Statements
Financial Obligations Parties Financial Results
Financial Results 2006 Financial Statements Exhibits
Find Information Flooring
Follows Cover Page Force Majeure
Forecast Delivery Ancrod Form 10-k
Form 10-q Form T-1
Form Transfer Notice Form Work Order
Former Name Address Changed Since Last Report Forward-looking Statements
Fractional Shares Further Development Research
Further Stockholder Approval Not Required Connection Implementation Dissolution General
General Administrative Expenses General Information
General Provisions General Release Not Extend Claims Creditor Know Suspect
General See Page General Study Assumptions
Going Concern Governing Law
Government Party Payors Fail Provide Coverage Adequate Payment Government Regulation
Grant Administration Grant Administration Costs
Grant Administration Payment Schedule Grant Payment Timelines
Grants Plan-based Awards Ground
Guarantees Indemnifications Heating Ventilating Air Conditioning
Held 2007 Held Friday 2007
Held Monday 2006 Held Monday 2008
Held Tuesday 2005 Held Tuesday 2009
Help Answer Questions Hereinafter Called 132nordmark
Hereinafter Called Nordmark Highlights Nti 2006
History Losses Expect Generate Near Future Never Achieve History Losses Never Achieve Maintain Profitability
Hotel Hotel Rooming List Date Neurobiological Technologies Inc Guarantee
Householding Householding Annual Disclosure Documents
Householding Proxy Materials Http Wwwntiicom
Http Wwwsecgov Icon Clinical Research Limited
Icon Clinical Research Xerecept Icon Key Personnel
Iconomics Set-up Iconomics Tracking
Icotrack Iconomics Impairment Charge Decrease Fair Value Investments
Impairment Charge Property Equipment Impairment Long-lived Assets
In-process Research Development Income Taxes
Incorporation Reference Indemnification
Indemnity Clinical Investigators Indemnity Insurance Scirex Nti
Independent Contractor Name Publication Independent Registered Public Accounting Firm
Index Index Consolidated Financial Statements
Industry Highly Competitive Infringement
Inherent Limitations Effectiveness Controls Insurance
Intellectual Property Intellectual Property Improvements
Interaction Communication Between Merz Allergan Interactive Voice Response System Ivrs
Interest Expense Interest Income
Interests Management Amendment Charter See Page Interests Management Approving Amendment Charter
Interests Management Dissolution Interests Management Dissolution See Page
Interior Wall Partition Systems Introduction
Investigative Drug Treatments Investigator Payments Administrator
Investigator Payments Assistant Investment Income
Investment Income Loss Invoicing
Irs Employer Identification Ischemic Stroke
Issuance Common Stock Warrants Issuer Respect Securities
Ivrs Costs Ivrs Payment Schedule
Ivrs Timelines Key Personnel
Kitchen Lunchroom Lease Addendum Scope Work Outline
Lease Commitments Leasehold Improvements
Legal Proceedings Liability
License Fees Profit Sharing License Grant
License Rights Viprinex Abbott Laboratories Life Safety Systems
Lighting Light Switches Limitation Deduction Certain Compensation
Limitation Incorporation Reference Limitation Liability
Limitation Liability Risk Loss Limited Control Over Development Commercialization Xerecept Rights Sold
Line Credit Liquidating Distributions
Liquidating Distributions Stockholders Delayed Diminished Liquidating Trust
Liquidating Trust See Page Liquidating Trusts
Liquidation Code Sections 331 336 Liquidity Capital Resources
List Other Countries Relating Listed Agreements
Making Available Technical Information Documents Manage Phase Trials Viprinex Ancrod Ischemic Stroke
Managements Report Internal Control Over Financial Reporting Manufacturing Supply
Market Opportunity Market Price Common Stock Been Likely Continue Highly
Market Registrants Common Equity Related Stockholder Matters Issuer Marketing Partner Develops Markets Memantine Merz Indication Cmcc
Marketing Partner Willing Develop Cmcc Indications Parties Entitled Master Clinical Development Agreement
Master Services Agreement Material Agreements
Material Contracts Material Effects Proposed Reverse Stock Split
Materials Delivery Payment Schedule Mechanism Action
Meet Stringent Ongoing Requirements Nasdaq Maintain Listing Common Meeting Collateral
Meeting Space Kalkscheune Minutes Walk Hilton Hotel Minimum Memantine
Members Expanded Management Team Unable Work Together Effectively Membership Power Act
Merz Patents Merz Pharmaceuticals Gmbh
Merz Pharmaceuticals Memantine Merz Responsibilities Obligations
Minimum Stock Ownership Requirements Miscellaneous
Miscellaneous Final Provisions Modifications
More- Mta Production
Name Person Filing Proxy Statement Other Registrant Nasdaq Listing
Nature Relationship Need Raise Additional Capital Fund Ongoing Operations Unable
Need Raise Additional Capital Reach Profitability Succeed Raising Net Income Loss Per Share
Net Loss Per Share Neurobiological Technologies Inc
Neurobiological Technologies Inc Announces Sale Xerecept Celtic Pharma Neurobiological Technologies Inc Audit Committee Charter Adopted Board
Neurobiological Technologies Inc Reports Results Neurobiological Technologies Reports Financial Results
Neuropathic Pain Diabetes Nominating Corporate Governance Committee
Nominating Process Nominees
Nominees Listed Below Non-cash Gain Change Fair Value Warrants
Non-cash Loss Gain Change Fair Value Warrants Non-compete Clause
Nonqualified Deferred Compensation Nordmark Arzneimittel Gmbh
Nordmarks Obligations Not Able Settle Obligations Creditors
Not Continue Attract Retain Key Employees Product Development Not Likely Continue Meet Listing Standards Nasdaq Capital
Not Own Manufacturing Facilities Dependent Contract Manufacturers Suppliers Notes
Notice Annual Meeting Stockholders Held Thursday 2008 Notice Exercise
Notice Holders Preferred Stock See Page Notices
Now Therefore Supplemental Indenture Witnesseth Nti Key Personnel
Ntis Responsibilities Obligations Object Scope
Obligations Obligations Nordmark
Obligations Nti Obligations Scirex
Off Balance Sheet Arrangements Off-balance Sheet Arrangements
Offering Contemplated Registration Statement Form S-1 Filed Sec Offering Space
Officers Only Limited Rights License Cooperation Agreement Merz Cmcc
Operating Lease Commitments Operating Leases
Option Exercises Options
Other Agreements Related Viprinex Other Benefits
Other Business Other Commitments
Other Comprehensive Loss Other Glass Glazing
Other Information Other Matters
Other Miscellaneous Other Non-cash Income
Outline Location Premises Outstanding Equity Awards Year-end
Overview Overview Key Developments 2009
Ownership Storage Parking
Parking Agreement Part
Part Other Informati Part Other Information
Pass-through Costs Patent Prosecution
Patent Rights Patents
Patents Patent Applications Patents Proprietary Information
Payment Schedule Payment Schedule Consultancy Services
Pension Benefits Performance Services
Peritumoral Brain Edema Plan
Plan Benefits Plan Summary
Plumbing Fixtures Potential Liability Stockholders
Potential Liability Stockholders See Page Potential Payments Termination Change Control
Potential Target Acquisition Power Signal Service
Powers Attorney Signatures Preamble
Preclinical Programs Licensed Buck Institute Age Research Preferred Share Purchase Rights
Primary Secondary Endpoints Principal Accountant Fees Services
Pro Forma Results Procedure Effecting Reverse Split Exchange Stock Certificates
Product Candidate-viprinex Product Candidates Based New Technologies Therefore Subject Numerous
Product Development Status Product Development Status Summary
Professional Fees Expenses Project Contract Protocol Nti 0302
Project Management Project Manager
Properties Property Equipment
Property Equipment Net Property Ownership
Proposal Proposal 1-to Amend 2003 Equity Incentive Plan
Proposal 2-to Adjourn Special Meeting Necessary Solicit Additional Proposals
Proposed Amendment Protein Shows Multiple Treatment Benefits Model Systems
Protocol Proxy Requirements Voting Proxies
Proxy Solicited Behalf Board Directors Proxy Statement
Purchase Price Allocation Purchase Sale Notes Common Stock
Purpose Purpose Background Reverse Split
Purpose Scope Cooperation Purposes
Quantitative Qualitative Disclosure Market Risk Quantitative Qualitative Disclosures Market Risk
Quarterly Period 2007 Quarterly Reports Provided Merz Cmcc Nti Accordance Shall
Quorum Required Votes Ratification Appointment Independent Registered Public Accounting Firm
Ratification Independent Registered Public Accounting Firm Reasons Amendment
Reasons Amendment See Page Reasons Dissolution Liquidation
Reasons Dissolution Liquidation See Page Reasons Proposed Amendments
Recent Accounting Pronouncement Recent Accounting Pronouncements
Recently Issued Accounting Standards Recently Several Changes Composition Management Team Expect Make
Recently Several Changes Composition Management Team Members Unable Recitals
Reclassification Recommendation Board
Recommendation Board See Page Record Date Voting Securities
Recordation Transfers Capital Stock Transfer Books Restricted Effective Records
Redemption Preferred Stock Payment Extraordinary Dividend Redemption Preferred Stock Payment Extraordinary Dividend See Page
Reduction Demised Premises Reduction Percentage Base Real Estate Taxes
Reduction Rent Refac Tenant
Registrants Telephone Number Including Area Code Regulatory Approvals
Regulatory Approvals See Page Regulatory Authorities Not Approve Viprinex Product Candidates Even
Regulatory Authority Reimbursement
Reimbursement Policy Related Party Transaction Review Approval
Related-party Transaction Review Approval Related-party Transactions
Relied Continue Rely Others Research Development Commercialization Potential Relied Continue Rely Parties Conduct Clinical Trials Viprinex
Report Adequacy Internal Controls Starting 2005 Auditors Attest Report Audit Committee
Report Compensation Committee Executive Report Ernst Young Llp Independent Registered Public Accounting
Report Independent Registered Public Accounting Firm Reporting
Reporting Requirements Reporting Requirements See Page
Reports Representation Warranties
Representations Warranties Required Vote
Required Vote See Page Research Development Expenses
Resolves Nasdaq Listing Deficiency Responsibilities
Restated Financial Results 2005 2006 Restatement
Restricted Cash Results
Results 2006 Results 2007
Results Nine-months 2007 Results Operations
Results Operations Financial Condition Results Six-months 2006
Revenue Recognition Revenues
Reverse Stock Split Revised Cost Estimation Phase Studies
Revocability Proxies Right Repurchase
Risk Factors Risks Related Approval Amendment Charter
Risks Related Business Risks Related Common Stock
Risks Related Continuing Business Operations Dissolution Pursuant Plan Risks Related Financial Condition
Risks Related Plan Dissolution See Page Role Executives Determining Compensation
Royalty Rights Memantine Cooperation Agreement Merz Cmcc Sale Rights Interests Xerecept
Sale Rights Xerecept Celtic Pharma Holdings Sarbanes-oxley Act 2002
Satisfaction Discharge Schedule
Scirex Corporation Securities
Securities Authorized Issuance Equity Compensation Plans Securities Exchange Act 1934
Securities Purchase Agreement Security Agreement
Security Forms Security Ownership Certain Beneficial Owners Management Related Stockholder
Selected Balance Sheet Data Selected Consolidated Balance Sheet Data
Series Convertible Preferred Stock Service Mechanics
Services Fees Severability
Signat Ures Signature
Signature Page Amendment Loan Security Agreement Signature Page Loan Security Agreement
Signature Page Supplemental Indenture Follows Signature Pages Follow
Signatures Sites Patients
Solicitation Proxies Space Definition
Sprinklers Standard Operating Procedures Sops
Status Reporting Stock Awards
Stock Option Grants 2005 Stock Option Grants 2006
Stock Options Stock Performance Graph
Stock Repurchase Program Stock-based Compensation
Stock-based Compensation Expense Stockholder Communications
Stockholder Proposals Stockholder Rights Plan
Stockholders Not Able Recognize Loss Federal Income Tax Stockholders Not Approve Dissolution Pursuant Plan Cash Resources
Stockholders Not Approve Dissolution Pursuant Plan Stock Price Stockholders Sharing Same Address
Stroke Background Study Information
Study Specifications Subject Agreement
Subject Cooperation Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Subsidiary Listed Agreement Subsidiary Registrant
Success Depend Large Part Ability Obtain License Patents Summary Amendment
Summary Amendment See Page Summary Compensation Table
Summary Term Sheet Supplemental Indentures
Suppliers Supply Api Starting Material
Supply Compound Bulk Memantine Finished Products Survival
System Development System Maintenance
Table Contents Tax Accounting Considerations
Tax Considerations Deductibility Executive Compensation Technical Specifications Snake Farm
Term Termination Terms Agreement
Timelines Timing Compensation
Toilet Room Finishes Trademarks
Transactions Related Parties Transfer Obligations
Transfer Responsibilities Transition Phase Future Uncertain
Translations Treatment Options
Treatment Options See Page Trial Design Statistical Considerations
Unresolved Staff Comments Utilities Meters
Valuation Acquisition-related Long-lived Tangible Intangible Assets Valuation Equity Financing Warrants
Valuation Long-lived Intangible Assets Viprinex
Viprinex Clinical Trial Overview Viprinex History
Viprinex Market Overview Viprinex Not Attain Adequate Market Acceptance Health Care
Viprinex Phase Trial Program Viprinex Subjects Beginning Treatment Within Onset Acute Ischemic
Vote Required Voting
Voting Revocation Proxy Waiver
Wall Coverings Paint Warrant Liability
Warranties Warrants Issued Connection Equity Financings
Warrants Purchase Common Stock Washington 20549
Witnesseth Work Letter
Xerecept Xerecept Human Corticotropin-releasing Factor
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki